Study details
Enrolling now
Synbiotic Compound to Reduce Symptoms of Schizophrenia
Sheppard Pratt Health System
NCT IDNCT04226898ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
18–65
Locations
1 site in MD
About this study
This Phase 2 study is testing Synbiotic Supplement in people with schizophrenia.
Based on ClinicalTrials.gov records.
PhasePhase 2
DrugSynbiotic Supplement
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
dietary supplement
Endpoints
Secondary: Intestinal Inflammation Markers (#4) C-reactive protein
Body systems
Psychiatry / Mental Health